This is what analysts have to say about Seres Therapeutics, Inc. (NASDAQ:MCRB) after last week.

May 13, 2018 - By Linda Rogers

Seres Therapeutics, Inc. (NASDAQ:MCRB) Logo

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 2 analysts covering Seres Therapeutics (NASDAQ:MCRB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics had 3 analyst reports since January 11, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 8 by Cantor Fitzgerald. Oppenheimer maintained the shares of MCRB in report on Tuesday, March 20 with “Buy” rating. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Buy” rating given on Thursday, January 11 by Oppenheimer. Below is a list of Seres Therapeutics, Inc. (NASDAQ:MCRB) latest ratings and price target changes.

20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
08/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $16.0 Maintain
11/01/2018 Broker: Oppenheimer Rating: Buy New Target: $19.0 Maintain

The stock increased 1.34% or $0.11 during the last trading session, reaching $8.32. About 121,326 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since May 13, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $338.23 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More important recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: which released: “Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and …” on May 07, 2018, also published article titled: “Seres Therapeutics’ (MCRB) CEO Roger Pomerantz on Q1 2018 Results – Earnings Call Transcript”, published: “Seres Therapeutics (MCRB) Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics …” on April 17, 2018. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) was released by: and their article: “Seres Therapeutics (MCRB) Reports Q1 Revenues Above Consensus” with publication date: May 09, 2018.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: